PAH

Phenylalanine hydroxylase (PAH) is the enzyme that converts L-phenylalanine to tyrosine using molecular oxygen and the cofactor tetrahydrobiopterin (BH4), and its loss of function causes hyperphenylalaninemia and phenylketonuria (PKU) (PMID:17443661). The dominant pathogenic mechanism is amino acid substitution-induced misfolding of the PAH monomer and/or failure to assemble into the native homotetramer, which accelerates cellular degradation and lowers steady-state enzyme levels, thereby reducing phenylalanine hydroxylation; residual in vitro activity of individual missense variants correlates with clinical metabolic severity (PMID:12655545, PMID:11708866). Splice-site mutations constitute a distinct mechanism: disruption of an invariant intronic GT donor activates cryptic splice sites, generating frameshifted, prematurely truncated transcripts and PAH deficiency (PMID:11161825). Complete loss of PAH protein and activity in liver reproduces classical PKU, and null monomers can form inhibitory heterotetramers with wild-type PAH (PMID:33051130). Beyond the enzyme defect itself, the resulting chronic phenylalanine accumulation drives a secondary epigenetic consequence: aberrant DNA methylation and altered gene expression in brain tissue, including differential methylation of noncoding/miRNA and synaptic genes, with the degree of alteration tracking phenylalanine exposure and reversible by dietary phenylalanine restriction (PMID:26822703, PMID:25990862). Genome-editing correction of the common p.Arg408Trp variant restores PAH enzymatic activity in a cellular model (PMID:27786189).

1. 2001 Medium

   Establishing that splice-site disruption is a mechanistically distinct route to PAH deficiency clarified that not all pathogenic alleles act through protein misfolding.

   Evidence cDNA and genomic sequencing of cryptic splice products in the PAHenu3 mouse model

   PMID:11161825

   Open questions at the time

   • Does not quantify the relative contribution of splice-site versus missense mechanisms across the human allele spectrum
   • Cryptic-site usage characterized in mouse, not directly in human tissue
2. 2001 Medium

   Direct expression of individual missense mutants quantified residual activity and linked it to clinical severity, grounding genotype-phenotype prediction.

   Evidence Eukaryotic expression (pCDNA3/COS-7) and enzymatic assay of L41F, T92I, P211T

   PMID:11708866

   Open questions at the time

   • Only three variants tested in a single lab
   • Does not resolve whether reduced activity reflects misfolding, instability, or catalytic impairment
3. 2003 High

   Systematic expression analysis across 81 mutations defined misfolding/failed tetramer assembly with accelerated degradation as the predominant disease mechanism, unifying many alleles under one model.

   Evidence In vitro expression in multiple eukaryotic cell systems with residual activity and protein-level quantification

   PMID:12655545

   Open questions at the time

   • Cellular degradation pathway not defined at the molecular level in this study
   • Does not address in vivo enzyme stability in liver
4. 2007 High

   Synthesis of decades of biochemistry consolidated the catalytic reaction, cofactor requirement, and the link of >500 loss-of-function alleles to hyperphenylalaninemia and PKU.

   Evidence Review integrating reconstituted enzymatic assays (EC 1.14.16.1) and genetic data

   PMID:17443661

   Open questions at the time

   • Review-level synthesis rather than new primary experiment
   • Does not address tissue-specific or downstream consequences of substrate accumulation
5. 2015 Medium

   Showing aberrant DNA methylation in PKU patient brain and leukocytes that scales with phenylalanine exposure introduced a secondary epigenetic mechanism downstream of the enzyme defect.

   Evidence MeDIP-seq of brain and leukocytes from classical/controlled PKU patients with expression analysis

   PMID:25990862

   Open questions at the time

   • Human data are observational and correlational, not causal
   • Mechanism linking phenylalanine to methylation machinery not defined
6. 2016 Medium

   Dietary rescue in the PAHenu2 mouse established phenylalanine itself as the causal driver of brain methylation changes, advancing the secondary mechanism from correlation toward causation.

   Evidence MeDIP-seq of brain under hyperphenylalaninemic versus phenylalanine-restricted diet with expression validation

   PMID:26822703

   Open questions at the time

   • Molecular pathway by which phenylalanine alters methyltransferase activity unresolved
   • Functional/behavioral consequences of specific methylation changes not demonstrated
7. 2016 Medium

   Genome-editing correction of the common p.Arg408Trp allele provided proof-of-concept that restoring the coding sequence recovers enzymatic activity.

   Evidence FokI-dCas9 editing with ssODN HDR template in c.1222C>T COS-7 cells; PAH activity assay

   PMID:27786189

   Open questions at the time

   • Demonstrated only in a cell model, not in liver in vivo
   • Editing efficiency and off-target profile not therapeutically validated
8. 2020 Medium

   A clean exon-1-deletion null mouse removed the confounding inhibitory heterotetramer effect, providing a definitive complete-loss-of-function PKU model.

   Evidence CRISPR/Cas9 embryonic deletion of Pah exon 1; liver activity, plasma phenylalanine, and Western blot

   PMID:33051130

   Open questions at the time

   • Heterotetramer inhibition is inferred from model rationale rather than directly assayed here
   • Does not address residual-activity (hypomorphic) disease forms

• The molecular pathway connecting phenylalanine accumulation to the DNA methylation machinery, and the route from misfolded monomers to proteasomal degradation in vivo, remain unresolved.
• No mechanism linking substrate accumulation to methyltransferase activity
• In vivo degradation pathway for misfolded PAH not characterized